Everads Therapy Overview
Everads Therapy is an early-stage life sciences company developing retinal treatment delivery technologies. The companys delivery system aims to improve the efficacy and safety of existing and potential drug therapies, with the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases. Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.
Cumulative Funding Raised Over Time ($)
$1.0MJan 2017
Latest News
growth-positive
/PRNewswire/ -- Everads Therapy, a clinical-stage company leveraging its novel suprachoroidal delivery technology to advance the treatment of retinal diseases,...
Everads Therapy, a clinical-stage company, has announced promising results from its first-in-human clinical trial and preclinical data at the 2025 American Society of Retina Specialists Annual Meeting. The companys novel suprachoroidal delivery technology, the Everads Injector, demonstrated safety, feasibility, and ease of use for treating retinal diseases, particularly diabetic macular edema and retinal detachment. The technology offers a minimally invasive, office-based treatment option, potentially transforming retinal detachment repair. Everads Therapy, a spin-out from DALI Medical Devices, collaborates with partners across various therapeutic modalities to maximize its delivery platforms potential.
Product StagePartners
growth-positive
/PRNewswire/ -- Everads Therapy, a clinical stage biotechnology company developing a platform for non-surgical delivery of therapeutics to the back of the eye...
Everads Therapy, a clinical-stage biotechnology company, presented promising initial clinical results from a first-in-human study at the 24th EURETINA Congress in Barcelona. The study demonstrated the safety, feasibility, and tolerability of the Everads Injector for delivering drugs to the back of the eye via the suprachoroidal space. These results validate the use of the Injector in a clinical, office-based setting and will support the clinical trial applications of Everads gene therapy license partners. The company is now recruiting patients for the next cohort, with full results expected at an upcoming medical congress. Everads technology aims to improve the efficacy and safety of treatments for retinal diseases through non-surgical delivery methods.
CustomersPartnersExpand
growth-positive
Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company
Everads Therapy has entered into a collaboration with a clinical-stage gene therapy company to evaluate suprachoroidal delivery for its gene therapy pipeline programs. The collaboration aims to explore the feasibility of using Everads delivery platform to deliver proprietary viral vectors to the choroid and retina. The financial terms of a future license have been agreed upon, including an upfront licensing fee, development-related milestones, and commercial royalties. Everads suprachoroidal delivery system enables safe and effective delivery of therapy to target choroidal and retinal tissues. The companys technology was licensed from the Sheba Medical Center and further developed in collaboration with DALI Medical Devices. Everads Therapy aims to restore vision in patients with retinal diseases through optimal treatment via suprachoroidal delivery.
Partners
growth-positive
Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets
Everads Therapy has announced a milestone achievement within its collaboration with a global pharmaceutical company. The company has granted exclusivity to the pharmaceutical company for utilizing its suprachoroidal delivery technology for specific ocular targets. In exchange, Everads will receive a milestone payment. The company retains the right to continue using and licensing its technologies for other therapies. The major pharmaceutical companys payment for exclusivity demonstrates the potential of Everads drug delivery technology. Everads is optimistic that the collaboration will lead to a commercial license. Everads Therapy is an ophthalmology-focused life-sciences company developing a revolutionary delivery system for suprachoroidal delivery of injectable therapies.
Partners
growth-positive
Everads Therapy wins retina commercialization option deal
Israeli medical company Everads Therapy has signed a commercialisation option agreement for its device that injects drugs into the back part of the eye. The device is aimed at treating retinal diseases such as dry AMD, wet AMD and other diabetic degenerative retinal diseases. The other company involved in the agreement, which markets drugs for ophthalmological diseases, was not named. The deal could potentially be worth billions of dollars. Everads will receive an upfront fee and payments for milestones, as well as a proportion of the other companys revenue if the product is integrated with their drug and reaches the market.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1M |
| Last funding | $1M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 2 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | www.everads-therapy.com/ |
Locations
HaBarzel Street 27, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
Everads Therapy Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsCore Technology
—Tags (12)
cell-therapyophthalmologymedical-devicesclinicshospitalsbiotechnologydoctorsdrug-deliverymedical-technologieseye-diseasesminimally-invasivenanotechnologyGeographic Markets
GlobalEverads Therapy Financials
$1M
Total funding
Undisclosed
Capital raised
$1M
Last funding
Seed
Funding stage
1
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$1.0MJan 2017
Private Equity Funding
Seed
Jan 2017
$1M
EU Horizon 2020, RAD BioMed
Everads Therapy Lifecycle
Cumulative Funding Raised Over Time
$1.0MJan 2017
All Events
Seed
Jan 2017
$1M
EU Horizon 2020, RAD BioMed
Everads Therapy News
6 articles
growth-positive
/PRNewswire/ -- Everads Therapy, a clinical-stage company leveraging its novel suprachoroidal delivery technology to advance the treatment of retinal diseases,...
Everads Therapy, a clinical-stage company, has announced promising results from its first-in-human clinical trial and preclinical data at the 2025 American Society of Retina Specialists Annual Meeting. The companys novel suprachoroidal delivery technology, the Everads Injector, demonstrated safety, feasibility, and ease of use for treating retinal diseases, particularly diabetic macular edema and retinal detachment. The technology offers a minimally invasive, office-based treatment option, potentially transforming retinal detachment repair. Everads Therapy, a spin-out from DALI Medical Devices, collaborates with partners across various therapeutic modalities to maximize its delivery platforms potential.
Product StagePartners
growth-positive
/PRNewswire/ -- Everads Therapy, a clinical stage biotechnology company developing a platform for non-surgical delivery of therapeutics to the back of the eye...
Everads Therapy, a clinical-stage biotechnology company, presented promising initial clinical results from a first-in-human study at the 24th EURETINA Congress in Barcelona. The study demonstrated the safety, feasibility, and tolerability of the Everads Injector for delivering drugs to the back of the eye via the suprachoroidal space. These results validate the use of the Injector in a clinical, office-based setting and will support the clinical trial applications of Everads gene therapy license partners. The company is now recruiting patients for the next cohort, with full results expected at an upcoming medical congress. Everads technology aims to improve the efficacy and safety of treatments for retinal diseases through non-surgical delivery methods.
CustomersPartnersExpand
growth-positive
Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company
Everads Therapy has entered into a collaboration with a clinical-stage gene therapy company to evaluate suprachoroidal delivery for its gene therapy pipeline programs. The collaboration aims to explore the feasibility of using Everads delivery platform to deliver proprietary viral vectors to the choroid and retina. The financial terms of a future license have been agreed upon, including an upfront licensing fee, development-related milestones, and commercial royalties. Everads suprachoroidal delivery system enables safe and effective delivery of therapy to target choroidal and retinal tissues. The companys technology was licensed from the Sheba Medical Center and further developed in collaboration with DALI Medical Devices. Everads Therapy aims to restore vision in patients with retinal diseases through optimal treatment via suprachoroidal delivery.
Partners
growth-positive
Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets
Everads Therapy has announced a milestone achievement within its collaboration with a global pharmaceutical company. The company has granted exclusivity to the pharmaceutical company for utilizing its suprachoroidal delivery technology for specific ocular targets. In exchange, Everads will receive a milestone payment. The company retains the right to continue using and licensing its technologies for other therapies. The major pharmaceutical companys payment for exclusivity demonstrates the potential of Everads drug delivery technology. Everads is optimistic that the collaboration will lead to a commercial license. Everads Therapy is an ophthalmology-focused life-sciences company developing a revolutionary delivery system for suprachoroidal delivery of injectable therapies.
Partners
growth-positive
Everads Therapy wins retina commercialization option deal
Israeli medical company Everads Therapy has signed a commercialisation option agreement for its device that injects drugs into the back part of the eye. The device is aimed at treating retinal diseases such as dry AMD, wet AMD and other diabetic degenerative retinal diseases. The other company involved in the agreement, which markets drugs for ophthalmological diseases, was not named. The deal could potentially be worth billions of dollars. Everads will receive an upfront fee and payments for milestones, as well as a proportion of the other companys revenue if the product is integrated with their drug and reaches the market.
Partners
growth-positive
Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies
Everads Therapy has signed an option agreement with a large global pharmaceutical company to evaluate its suprachoroidal delivery system. This is Everads first commercial agreement and supports the potential of its technology to improve retinal disease treatment options. The agreement grants the pharma company an exclusive option to enter into a license agreement for the use of Everads delivery system. The company believes its delivery system overcomes technical challenges and may provide superior outcomes compared to current injection methods. The goal is to improve the treatment of macular disease. Everads Therapy is a life sciences company operating within the RAD Biomed incubator in Tel Aviv, Israel.
Partners
Everads Therapy Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 10 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Everads Therapy Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| BI Verification | Vered Waxman |
| Registrar ID | 515541324 |
| Crunchbase | everads-therapy |
| Phone | +97237684943 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-22T00:00:00.000Z |
| Created | 2019-05-30T00:00:00.000Z |
| Claimed | Yes |